Dimensional Fund Advisors LP Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Posted by Defense World Staff on May 24th, 2023

Dimensional Fund Advisors LP boosted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) by 5.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,383,345 shares of the specialty pharmaceutical company’s stock after buying an additional 112,865 shares during the period. Dimensional Fund Advisors LP owned 4.41% of Supernus Pharmaceuticals worth $85,015,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Meritage Portfolio Management raised its position in Supernus Pharmaceuticals by 3.0% in the fourth quarter. Meritage Portfolio Management now owns 12,601 shares of the specialty pharmaceutical company’s stock valued at $449,000 after purchasing an additional 365 shares during the period. Public Employees Retirement System of Ohio boosted its stake in Supernus Pharmaceuticals by 41.6% during the third quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 368 shares during the period. IFP Advisors Inc increased its position in shares of Supernus Pharmaceuticals by 17.7% during the third quarter. IFP Advisors Inc now owns 2,923 shares of the specialty pharmaceutical company’s stock valued at $164,000 after acquiring an additional 440 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its stake in shares of Supernus Pharmaceuticals by 4.2% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 12,724 shares of the specialty pharmaceutical company’s stock valued at $431,000 after acquiring an additional 510 shares during the period. Finally, Eagle Bay Advisors LLC lifted its holdings in shares of Supernus Pharmaceuticals by 19.3% in the 4th quarter. Eagle Bay Advisors LLC now owns 3,186 shares of the specialty pharmaceutical company’s stock worth $114,000 after acquiring an additional 515 shares during the last quarter. Institutional investors and hedge funds own 99.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SUPN. StockNews.com began coverage on Supernus Pharmaceuticals in a research report on Thursday, May 18th. They issued a “buy” rating on the stock. Piper Sandler raised their target price on Supernus Pharmaceuticals from $45.00 to $46.00 in a report on Wednesday, May 10th. Finally, TheStreet lowered shares of Supernus Pharmaceuticals from a “b+” rating to a “c+” rating in a research note on Friday, May 12th.

Supernus Pharmaceuticals Trading Down 1.3 %

Supernus Pharmaceuticals stock opened at $34.06 on Wednesday. The firm has a market capitalization of $1.86 billion, a P/E ratio of 38.27 and a beta of 1.04. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.80 and a twelve month high of $42.09. The stock’s fifty day simple moving average is $36.25 and its 200-day simple moving average is $37.10.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.17. Supernus Pharmaceuticals had a return on equity of 5.96% and a net margin of 7.79%. The company had revenue of $153.80 million for the quarter, compared to analyst estimates of $139.02 million. During the same quarter last year, the company earned $0.43 EPS. Supernus Pharmaceuticals’s revenue for the quarter was up .9% compared to the same quarter last year. Sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 1.31 earnings per share for the current year.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 4,780 shares of the stock in a transaction that occurred on Tuesday, March 14th. The shares were sold at an average price of $35.99, for a total value of $172,032.20. Following the sale, the senior vice president now directly owns 4,737 shares of the company’s stock, valued at approximately $170,484.63. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.70% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Profile

(Get Rating)

Supernus Pharmaceuticals, Inc engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.